DEFR14A: Panbela Therapeutics Reschedules Special Meeting, Proposes Reverse Stock Split

Panbela Therapeutics has rescheduled its Special Meeting of Stockholders to May 28, 2024, and is seeking approval for a reverse stock split to meet listing requirements.

Summary

• Panbela Therapeutics has rescheduled its Special Meeting of Stockholders from May 3, 2024, to May 28, 2024.
• The meeting will address an amendment to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its outstanding common stock.
• The reverse stock split ratio will range from 1-for-10 to 1-for-45, subject to the Board of Directors' determination.
• The company is also seeking approval to adjourn the Special Meeting if necessary to solicit additional proxies.
• The record date for determining stockholders eligible to vote at the Special Meeting has been changed to April 24, 2024.
• On April 23, 2024, the company issued one share of Series A Preferred Stock with specific voting rights regarding the reverse stock split proposal.
• The Board of Directors recommends voting FOR both the reverse stock split and the adjournment proposals.
• As of April 24, 2024, there were 4,854,861 shares of Common Stock outstanding.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the reverse stock split proposal and the rescheduling of the special meeting. The potential benefits of the reverse stock split are mentioned, but so are the risks and uncertainties.

Positives

• The reverse stock split aims to increase the stock price to meet listing requirements, potentially improving marketability and attracting institutional investors.
• The company is actively pursuing uplisting on the CBOE, which could enhance its visibility and access to capital.
• The Preferred Stock's voting structure mirrors the Common Stock votes, ensuring the Common Stock holders' preferences are reflected.
• The company intends to maintain the existing eligibility for quotation of its Common Stock on the OTCQB under its current symbol, PBLA.

Negatives

• Reverse stock splits can be perceived negatively by investors and may not guarantee a sustained increase in stock price.
• The reduced number of outstanding shares after the reverse stock split could adversely affect liquidity.
• The Board has the right to abandon the reverse stock split even if approved by stockholders, creating uncertainty.
• The company's Common Stock was delisted from Nasdaq and trading was suspended on March 7, 2024.

Risks

• There is no assurance that the reverse stock split will increase the stock price or enable the company to uplist or maintain listing on a national securities exchange.
• The market price of the Common Stock may decrease due to factors unrelated to the reverse stock split, such as future performance or general market trends.
• The reverse stock split may decrease the liquidity of the Common Stock and result in higher transaction costs.
• If the Board authorizes the issuance of additional shares of Common Stock subsequent to the Reverse Stock Split, the dilution to the ownership interest of our existing stockholders may be greater than would occur had the Reverse Stock Split not been effected.

Future Outlook

The company aims to increase its stock price to meet listing requirements and is pursuing uplisting on the CBOE. The Board reserves the right to abandon the reverse stock split if it's not in the company's best interest.

Management Comments

• The Board of Directors recommends voting FOR both the reverse stock split and the adjournment proposals.
• The Board determined that it was in the best interests of the Company and its stockholders to provide for supermajority voting of the Preferred Stock in order to obtain sufficient votes for the Reverse Stock Split proposal.

Industry Context

Reverse stock splits are often used by companies facing delisting to regain compliance with exchange listing requirements. The success of a reverse stock split depends on various factors, including the company's underlying financial health and market conditions.

Comparison to Industry Standards

• Many companies facing delisting from major exchanges have implemented reverse stock splits to try and regain compliance.
• The effectiveness of a reverse stock split varies widely, with some companies experiencing a sustained increase in stock price while others see only a temporary bump or further decline.
• Comparable companies that have used reverse stock splits include those in the biotechnology and pharmaceutical sectors facing similar listing challenges.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, potentially seeing a change in the number of shares they own and the market price per share.
• Employees may be impacted by the company's ability to maintain its listing and access capital.
• The company's creditors and suppliers may be affected by the company's financial stability and access to capital.

Next Steps

• Stockholders to vote on the reverse stock split and adjournment proposals at the Special Meeting on May 28, 2024.
• The Board of Directors will determine whether to implement the reverse stock split based on various factors.
• The company will pursue uplisting on the CBOE.

Key Dates

Keywords

reverse stock split, proxy statement, special meeting, Panbela Therapeutics, stockholders, CBOE, delisting, common stock, preferred stock, voting rights